今年将加速产品的国际化拓展。本文为IPO早知道原创作者|罗宾据IPO早知道消息,3月29日,荃信生物(2509.HK)公布了2024年全年业绩。2024年,公司实现收入人民币1.59亿元,首次实现营业收入。毛利达到9219万元。公司行政支出同比下降29.57%至1.16亿元;研发支出下降8.27%至3.34亿元。现金储备上升47.63%至5.56亿元,年内净亏损缩窄33%。2024年,荃信生物收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.